Evotec's Strategic Pivot Fueled by Unexpected Windfall

Evotec to gain ~$100M from Gilead's Tubulis buyout in 2026, aiding its 'Horizon' restructuring plan to cut costs and target profitability by 2030.

A significant cash injection from a past investment is providing crucial breathing room for Evotec SE as the Hamburg-based biotech firm executes a deep and painful corporate restructuring. The company stands to receive approximately $100 million in the second quarter of 2026 from Gilead Sciences' $3.15 billion acquisition of Tubulis, in which Evotec holds a 3.14% stake. Analysts suggest this financial boost, equivalent to about 11% of Evotec's market capitalization, may not yet be fully reflected in the stock's current valuation.

The final figures for 2025 showed signs of operational improvement against a challenging backdrop. Group revenue remained stable at EUR 788.4 million, while the adjusted EBITDA climbed to EUR 41.1 million, hitting the upper end of the company's guidance. The Just – Evotec Biologics division was a key growth driver, surging nearly 40% thanks to a major collaboration with Sandoz. Consequently, the net loss was nearly halved to roughly EUR 104 million from EUR 196 million a year earlier.

Despite this progress, management is forging ahead with an aggressive cost-cutting strategy dubbed "Horizon." The plan involves closing four of its 14 global sites and eliminating around 800 positions. These measures are expected to incur restructuring costs of about EUR 100 million in the second half of 2026 but are projected to deliver annual savings of approximately EUR 75 million from the end of 2027 onward.

For the current year, Evotec has tempered expectations, declaring 2026 a transitional period. The company forecasts revenue between EUR 700 million and EUR 780 million, with adjusted EBITDA expected to land between zero and EUR 40 million. This cautious outlook is mirrored in the share price, which recently traded at EUR 4.47, perilously close to its 52-week low of EUR 4.14 and continuing a downward trend since the start of the year.

The Tubulis deal proceeds offer vital liquidity to fund the expensive implementation of the new site structure. An additional $58 million could follow if certain milestones are achieved. The windfall strengthens Evotec's balance sheet as it works toward confirmed medium-term targets, which envision revenue exceeding one billion euros by 2030.

Overseeing this strategic overhaul will likely be a new chairman. Industry veteran Dieter Weinand, with decades of experience at firms like Bayer and Pfizer, is set to be elected as chairman of the supervisory board at the upcoming 2026 Annual General Meeting. His appointment is seen as a move to guide the strategic realignment while management focuses on cutting operational costs and integrating the Tubulis capital.

Analysts remain watchful. RBC Capital Markets maintained its "Outperform" rating on Evotec with a price target of EUR 10. Analyst Charles Weston highlighted the market's potential underestimation of the Tubulis cash infusion, noting its substantial proportion to the company's total market value.